Spero Therapeutics(SPRO) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update CAMBRIDGE, Mass., May 13, 2025 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. "At Spero, our top priority remains the successf ...